JNJ

155.49 USD

-1.24 (-0.79%)

Last updated Nov 8, 2:30 PM

Yesterday High

$158.65

Yesterday Low

$156.51

52w High

$167.39

52w Low

$144.38

Market Cap.

$374.2B

52w Change

5.32%

This is a preview of the full version of Prosperse

Trending News

L’association RYBREVANT®▼ (amivantamab) plus chimiothérapie démontre un taux de réponse globale de 49 pour cent dans le cancer colorectal métastatique
L’association RYBREVANT®▼ (amivantamab) plus chimiothérapie démontre un taux de réponse globale de 49 pour cent dans le cancer colorectal métastatique

Janssen-Cilag International NV announced new data from the OrigAMI-1 phase 1b/2 study, which showed that amivantamab combined with chemotherapy (mFOLFOX6 or FOLFIRI) demonstrated promising, rapid, and durable anti-tumor activity in patients with RAS/BRAF wild-type metastatic colorectal cancer who ha...

Janssen-Cilag International Nv

Sep 16, 2024

New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer

Janssen-Cilag International NV, a Johnson & Johnson company, announced positive results from the Phase 2b SunRISe-1 study, showing an 84% complete response rate with their investigational TAR-200 monotherapy in patients with high-risk non-muscle-invasive bladder cancer who are Bacillus Calmette-Guér...

Janssen-Cilag International Nv

Sep 15, 2024

RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
RYBREVANT®▼ (amivantamab) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated...

Amivantamab plus chemotherapy showed a positive overall survival trend and significant improvements in post-progression outcomes compared to chemotherapy alone in patients with previously treated EGFR-mutated non-small cell lung cancer.

Janssen-Cilag International Nv

Sep 14, 2024

Bipolar Disorder Market Size to Reach USD 7 Billion by 2033, Says The Brainy Insights
Bipolar Disorder Market Size to Reach USD 7 Billion by 2033, Says The Brainy Insights

The global bipolar disorder market is expected to grow from $5.2 billion in 2023 to $7 billion by 2033, driven by increasing prevalence, government initiatives, and technological advancements. However, side effects of medications and misdiagnosis pose challenges.

The Brainy Insights

Sep 13, 2024

Should You Buy Novavax Stock After This Regulatory Win?
Should You Buy Novavax Stock After This Regulatory Win?

Novavax, a vaccine maker, has received emergency use authorization from the FDA for its updated COVID-19 vaccine. However, the company is expected to play a secondary role in the market, and its long-term prospects remain uncertain due to its partnership with Sanofi and the development of its own pr...

Prosper Junior Bakiny

Sep 13, 2024

ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing
ONL Therapeutics Closes $65 Million in Oversubscribed Series D Financing

ONL Therapeutics, a clinical-stage biopharmaceutical company, has secured $65M in Series D financing led by Johnson & Johnson Innovation – JJDC, Inc. The funds will be used to advance the development of ONL1204 Ophthalmic Solution, a novel treatment for geographic atrophy associated with dry age-rel...

N/A

Sep 13, 2024

Login to view more news

Dive into the world of investing with Prosperse

Explore our recent articles to learn more about how Prosperse can help you achieve your financial goals.

Read more news from Prosperse